Influence of socio-cultural factors on hepatitis B infection in Mombasa County, Kenya
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20230907Keywords:
Hepatitis B, Injecting drug users, Prevalence, Socio-culturalAbstract
Background: The hepatitis B virus (HBV) is responsible for causing a communicable liver disease that can be prevented through vaccination. Although the HBV vaccine was introduced in Kenya’s expanded immunization program in 2003, the incidence of HBV remains high in the country, especially among IDUs. Objective was to investigate the influence of socio-cultural factors on HBV infection in Mombasa County, Kenya.
Methods: The study utilized a cross-sectional analytical design. The study was purposely conducted in Mombasa County because the area is highly prevalent with drug users and people with hepatitis B. There are eight treatment centers in the county, 4 public and 4 privates where stratified random sampling was used. The sample size was proportionately distributed across the selected treatment centers. The study employed a mixed method of data collection, involved; self-administered questionnaire to the IDU’s, key informant interviews and focused group discussion with treatment care managers.
Results: The prevalence of hepatitis B was 22%; with male (77.1%) most affected than women (22.9%). Bivariate analysis show that a history of drug abuse was significantly associated with prevalence of hepatitis B (χ2=2.485, df=1, p=0.046).
Conclusions: The prevalence of hepatitis B is on the increase among injecting drug users. Having a history of drug abuse was a significant predictor to the prevalence of hepatitis B among injecting drug users in this study. Cultural practices such as piercing and tattooing were observed among study participants were established as a risk factor to hepatitis B infection among injecting drug users.
Metrics
References
World Health Organization (WHO). World Cancer Report 2020: Cancer research for cancer prevention. International Agency for Research on Cancer. IARC; 2020 Available from: http://publications.iarc.fr/586. Accessed on 7 November 2022.
Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of chronic hepatitis B virus infection in the United States. Am J Gastroenterol; 2020;115:1429-38.
United Nations Office on Drugs and Crime [UNODC]. World Drug Report 2021: pandemic effects ramp up drug risks, as youth underestimate cannabis dangers. 2021. Available from: https://www.unodc.org/ropan/en/unodc-world-drug-report-2021_-pandemic-effectsramp-updrug-risks--as-youth-underestimate-cannabis-danger.html. Accessed on 23 January 2023.
Mercy JK, Fatuma Faraj S, Hellen Irusa Lukhaka D, Eric Wang’welo D, Laban Kipkemei M, Adrian G. Burden of hepatitis B Infection among high risk populations in western Kenya. J Infect Dis Epidemiol. 2020;6(3).
WHO. Substance Abuse. WHO. Regional Office for Africa. World Health Organization. 2021. Available from: https://www.afro.who.int/health-topics/substance-abuse. Accessed on 23 January 2023.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-55.
World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Available from: https://apps.who.int/iris/bitstream/handle/ 10665/246177/who?sequence=1. Accessed on 23 January 2023.
Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020;33(2):e00046-19.
Nguyen MH, Burak Ozbay A, Liou I, Meyer N, Gordon SC, Dusheiko G, et al. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. J Hepatol. 2019;70(1):24-32.
Liu A, Le A, Zhang J, Wong C, Wong C, Henry L, et al. Increasing co-morbidities in chronic hepatitis B patients: Experience in primary care and referral practices during 2000-2015 original-contribution. Clin Transl Gastroenterol. 2018;9(3).
Lin CL, Kao JH. Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol. 2017;31(3):249-55.
World Health Organization (WHO). Hepatitis B. Vol. 99, American family physician. 2022. Available from: https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b. Accessed on 7 November 2022.
Chang MH, You SL, Chen CJ, Liu CJ, Lai MW, Wu TC, et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology. 2016;151(3):472-480.e1.
Masudi OB. Factors influencing drug abuse among the youth in Mombasa County, Kenya University of Nairobi, Kenya. 2011.
Mehmood S, Raza H, Abid F, Saeed N, Rehman HM, Javed S, et al. National prevalence rate of hepatitis B and C in Pakistan and its risk factors. J Public Health. 2020;28:751-64.
Cai Y, Dai Z, Wen S, Bhandari R. Risk factors associated with infection of blood-borne virus among people who used methamphetamine. BMC Infect Dis. 2020;20(1).
Jose-Abrego A, Panduro A, Fierro NA, Roman S. High prevalence of HBV infection, detection of subgenotypes F1b, A2, and D4, and differential risk factors among Mexican risk populations with low socioeconomic status. J Med Virol. 2017;89(12):2149-57.
Józsa K, Morgan GA. Reversed items in likert scales: Filtering out invalid responders. J Psychol Educ Res. 2017;25(1):7-25.
Ceesay A, Lemoine M, Cohen D, Chemin I, Ndow G. Clinical utility of the “determine HBsAg” point-of-care test for diagnosis of hepatitis B surface antigen in Africa. Expert Rev Mol Diagn. 2022;22(5):497-505.
Hashemi-Shahri SM, Sharifi-Mood B, Metanat M, Salehi M, Sharifi R. Blood-borne infections in tattooed people. Int J Infect. 2016;3(2):34944.
Said BA, Hassan RAR. Risk factors for hepatitis b virus among blood donors in Baghdad, Iraq. Int J Adv Res Med. 2019;1(2):62-7.
Almasi-Hashiani A, Ayubi E, Mansori K, Salehi-Vaziri M, Moradi Y, Gholamaliei B, et al. Prevalence of hepatitis B virus infection among Iranian high risk groups: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2018;11:91-100.
Asli M, Kandelouei T, Rahimyan K, Davoodbeglou F, Vaezjalali M. Characterization of occult hepatitis B infection among injecting drug users in Tehran, Iran. Hepat Mon. 2016;16(3).
